Chemotherapy in osteosarcoma: The Scandinavian Sarcoma Group experience

Acta Orthopaedica Scandinavica

Volumn 75, Issue sup311, 2004, Pages 92-98

  Smeland, S ^a   Wiebe, T ^b   Bohling T ^c   Brosjo O ^d   Jonsson, K ^b   Alvegard T A ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE;

ACUTE TOXICITY; ADJUVANT CHEMOTHERAPY; BONE MARROW TOXICITY; BONE METASTASIS; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; COLITIS; CORRELATION ANALYSIS; ELECTROLYTE DISTURBANCE; HEART PROTECTION; HUMAN; NEUTROPENIA; OSTEOSARCOMA; PREOPERATIVE TREATMENT; RECURRENT DISEASE; REVIEW; SALVAGE THERAPY; SEPSIS; SURVIVAL RATE; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CLINICAL PROTOCOLS; DISEASE-FREE SURVIVAL; HUMANS; INTERFERON-ALPHA; MULTICENTER STUDIES; OSTEOSARCOMA; RANDOMIZED CONTROLLED TRIALS; SCANDINAVIA;

EID: 2342584092     PISSN: 00016470     EISSN: 17453682     Source Type: Journal    
DOI: 10.1080/00016470410001708380     Document Type: Article

References (21)

1. Bacci G, Picci P, Ferrari S et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Cancer 1993; 72: 3227 – 38.
2. Bielack SS, Eittniann R, Kempf-Bielack B, Winkler K. Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties?Eur J Cancer. 1996; 32: 1652 – 60.
3. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. Journal of Clinical Oncology 2002; 20: 776 – 90.
4. Ferrari S, Briccoli A, Mercuri M et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol. 2003; 15: 710 – 5.
5. Friedman MA, Carter SK. The therapy of osteogenic sar-coma: current stuatus and thoughts for the future. J Surg Oncol 1972; 4: 482 – 510.
6. Fuchs N, Bielack SS, Epler D et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 1998; 9: 893 – 9.
7. Harvei S, Solheim O. The prognosis in osteosarcoma: Nor-wegian national data. Cancer 1981; 48: 1719 – 23.
8. Huvos AG. Osteogenic sarcoma. In Huvos AG, ed. Bone Tumors. Diagnosis, Treatment and Prognosis. Philadel-phia, WB Saunders, 1991: 85 – 155.
9. Jaffe N Osteogenic sarcoma: state of the art with high-dose methotrexate treatment. Clin Orthop 1976; (120): 95 – 102.
10. Meyers PA, Schwartz CL, Bernstein M, et al. Addition of ifosfamide and muramyl tripeptide to cisplatin, doxorubicin and high-dose methotrexate improves event-free survival (EFS) in localized osteosarcoma (OS). Proceedings of the American Society of Clinical Oncology 2001; 20: 1463a.
11. Rosen G, Murphy ML, Huvos AG et al. Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery. Cancer 1979; 43: 2163 – 77.
12. Rosen G, Caparros B, Huvos AG et al. Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumour to preoperative chemotherapy. Cancer 1982; 49: 1221 – 30.
13. Saeter G, Alvegird TA, Elomaa I et al. Treatment of oste-osarcoma of the extremities with teh T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: A Scandi-navian Sarcoma Group study. J Clin Oncol 1991; 9: 1766 – 75.
14. Swter G, Bruland OS. High-grade osteosarcoma (OS): the scope beyond the “classical ” patient. In Towards the eradication os osteosarcoma metastases: an Odyssey 1998: 21 – 23.
15. Swter G, Hoie J, Stenwig, AE, et al. Systemic relapse of patients with osteogenic sarcoma: prognostic factors for long-term survival. Cancer 1995; 75: 1084 – 93.
16. Swter G, Wiebe T, Wiklund T et al. Chemotherapy in osteosarcoma. The Scandinavian Sarcoma group experience. Acta Orthop Scand (Suppl 285) 1999; 70: 74 – 82.
17. Serra M, Scotlandi K, Reverter-Branchat G et al Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J Clin Oncol. 2003; 21: 536 – 42.
18. Smeland S, Muller C, Alvegard TA et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: Prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histologic responders. Eur J Cancer, 2003; 39: 488 – 94.
19. Smeland S, Mifiler C, Saeter G. Reply to comment on “Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders Eur J Cancer. 2003; 39: 2567 – 8.
20. Smeland S, Bacci G, Ferrari S, et al. Neoadjuvant chemotherapy with high-dose ifosfamide added to methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity. A joint study by the Italian (ISG) and Scandinavian (SSG) sarcoma groups. Proceedings of the American Society of Clinical Oncology 2003b; 22: 3282a.
21. Strander H, Bauer HC, Brosjo O, et al. Long-term adjuvant interferon treatment of human osteosarcoma: a pilot study. Acta Oncologica 1995; 34: 877 – 80.